Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

Sholl LM, Aisner DL, Allen TC, Beasley MB, Cagle PT, Capelozzi VL, Dacic S, Hariri LP, Kerr KM, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao M, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2016 Aug;140(8):825-9. doi: 10.5858/arpa.2016-0163-SA. Epub 2016 May 19.

PMID:
27195432
2.

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.

Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A, Brandes AA, Venturino P, Cuccurullo F, Crinò L, Buttitta F.

PLoS One. 2014 Aug 19;9(8):e103883. doi: 10.1371/journal.pone.0103883. eCollection 2014.

3.

Liquid biopsy and its role in an advanced clinical trial for lung cancer.

Johann DJ Jr, Steliga M, Shin IJ, Yoon D, Arnaoutakis K, Hutchins L, Liu M, Liem J, Walker K, Pereira A, Yang M, Jeffus SK, Peterson E, Xu J.

Exp Biol Med (Maywood). 2018 Feb;243(3):262-271. doi: 10.1177/1535370217750087. Review.

PMID:
29405770
4.

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.

Vendrell JA, Mau-Them FT, Béganton B, Godreuil S, Coopman P, Solassol J.

Int J Mol Sci. 2017 Jan 29;18(2). pii: E264. doi: 10.3390/ijms18020264. Review.

5.

Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.

Takai E, Yachida S.

World J Gastroenterol. 2016 Oct 14;22(38):8480-8488. Review.

6.

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.

Yi X, Ma J, Guan Y, Chen R, Yang L, Xia X.

Int J Cancer. 2017 Jun 15;140(12):2642-2647. doi: 10.1002/ijc.30620. Epub 2017 Mar 2. Review.

7.

The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.

Esposito A, Criscitiello C, Trapani D, Curigliano G.

Curr Oncol Rep. 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y. Review.

PMID:
28110461
8.

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.

Lin CC, Huang WL, Wei F, Su WC, Wong DT.

Expert Rev Mol Diagn. 2015;15(11):1427-40. doi: 10.1586/14737159.2015.1094379. Epub 2015 Sep 30. Review.

9.

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.

Calapre L, Warburton L, Millward M, Ziman M, Gray ES.

Cancer Lett. 2017 Sep 28;404:62-69. doi: 10.1016/j.canlet.2017.06.030. Epub 2017 Jul 4. Review.

10.

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.

Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M, Souquet PJ; BioCAST/IFCT-1002 investigators.

Clin Cancer Res. 2014 Sep 1;20(17):4613-24. doi: 10.1158/1078-0432.CCR-13-3063. Epub 2014 Jul 10.

11.

Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy.

Schlange T, Pantel K.

Pharmacogenomics. 2016 Feb;17(3):183-6. doi: 10.2217/pgs.15.163. Epub 2016 Jan 22. No abstract available.

12.

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.

Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R.

Oncotarget. 2016 Mar 1;7(9):9707-17. doi: 10.18632/oncotarget.7110.

13.

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

Alix-Panabières C, Pantel K.

Cancer Discov. 2016 May;6(5):479-91. doi: 10.1158/2159-8290.CD-15-1483. Epub 2016 Mar 11. Review.

14.

Circulating Cell-Free Tumour DNA in the Management of Cancer.

Francis G, Stein S.

Int J Mol Sci. 2015 Jun 19;16(6):14122-42. doi: 10.3390/ijms160614122. Review.

15.

Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients.

Goto T, Hirotsu Y, Oyama T, Amemiya K, Omata M.

Med Oncol. 2016 Mar;33(3):29. doi: 10.1007/s12032-016-0744-x. Epub 2016 Feb 20.

PMID:
26897174
16.

[Blood-based Tumor Markers in Lung Cancer].

Zhou C.

Zhongguo Fei Ai Za Zhi. 2015 Dec;18(12):770-80. doi: 10.3779/j.issn.1009-3419.2015.12.10. Review. Chinese.

17.

Research progress on liquid biopsy in oncology and its clinical applications.

Wang C, Li YM, Fang XD.

Yi Chuan. 2017 Mar 20;39(3):220-231. doi: 10.16288/j.yczz.16-386. Review.

PMID:
28420618
18.

Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.

Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Lours C, Rozenholc Y, Taly V, Laurent-Puig P, Blons H, Fabre E.

PLoS Med. 2016 Dec 27;13(12):e1002199. doi: 10.1371/journal.pmed.1002199. eCollection 2016 Dec.

19.

Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.

Yu XM, Wu YC, Liu X, Huang XC, Hou XX, Wang JL, Cheng XL, Mao WM, Ling ZQ.

Int J Mol Sci. 2016 Nov 5;17(11). pii: E1845.

20.

Liquid Biopsies in Oncology and the Current Regulatory Landscape.

Strotman LN, Millner LM, Valdes R Jr, Linder MW.

Mol Diagn Ther. 2016 Oct;20(5):429-36. doi: 10.1007/s40291-016-0220-5. Review.

PMID:
27324559

Supplemental Content

Support Center